MedTrace Logo

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

NCT00667121 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 88

Last updated 2025-02-14

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood in the laboratory from patients receiving tamoxifen may help doctors learn more about the effects of other drugs on the level of tamoxifen in the blood.

PURPOSE: This clinical trial is studying levels of tamoxifen in the blood of women with breast cancer and in women at high risk of breast cancer who are receiving tamoxifen together with venlafaxine, citalopram, escitalopram, gabapentin, or sertraline.

Conditions

Interventions

DRUG

citalopram hydrobromide

DRUG

escitalopram oxalate

DRUG

gabapentin

DRUG

sertraline hydrochloride

DRUG

tamoxifen citrate

DRUG

venlafaxine

GENETIC

molecular genetic technique

OTHER

high performance liquid chromatography

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

PROCEDURE

adjuvant therapy

Sponsors & Collaborators

Principal Investigators

  • Matthew P. Goetz, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-16
Primary Completion
2014-05-12
Completion
2014-05-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00667121 on ClinicalTrials.gov